小肝癌中CD82和VEGF表达与术后复发关系

目的]研究KAI1/CD82和VEGF在小肝癌中的表达及其与临床病理及复发的关系。方法]用免疫组化SP法检测40例小肝癌组织、35例肝癌旁组织、5例肝腺瘤组织及5例肝血管瘤旁肝组织中CD82及VEGF蛋白的表达,并结合临床病理指标和生存资料进行分析。结果]CD82在小肝癌中表达率为40.0%(16/40),明显低于血管瘤旁肝组织100.0%(5/5)、肝腺瘤组织100.0%(5/5)和肝癌旁组织100.0%(35/35)(P<0.05);VEGF在小肝癌中的表达率为85%(34/40),明显高于血管瘤旁肝组织40.0%(2/5)和肝癌旁组织42.8%(15/35)(P<0.05)。CD82与VEGF蛋白表达之间无相关关系;CD82阴性组复发率高于CD82阳性组(54.2%vs.18.8%)(P=0.026);CD82阳性组累积1、2、3年无瘤生存率分别为94%、87%、68%,CD82阴性组累积1、2、3年无瘤生存率分别为85%、78%、43%;VEGF阴性组复发率低于阳性组(0vs.47.1%)(P=0.035);两者联合检测的灵敏度为81.3%,特异度为62.5%。结论]CD82与VEGF均与小肝癌术后复发相关,CD82有可能成为肝癌复发预测指标。

Expressions Relationship Between CD82 and VEGF and Postoperative Recurrence in Small Hepatocellular Carcinoma

Purpose] To investigate KAI1/CD82 and VEGF expressions and their relationship with clinicopathological profile and postoperative recurrence in small hepatocellular carcinoma (SHCC). Methods] Expression of CD82 and VEGF was determined by immunohistochemistry technique (S-P method) in 40 cases of SHCC tissue, 35 cases of SHCC adjacent liver tissue, 5 cases of hepatic adenoma tissue and 5 cases of normal liver tissue from liver angioma. The expressions with the clinicopathological profile and survival were analyzed. Results] Positive expression rate of CD82 protein in SHCC was 40% (16/40), which was significantly lower than that in the normal liver tissue from liver angioma (100%, 5/5), hepatic adenoma tissue (100%, 5/5), SHCC adjacent liver tissue (100%, 35/35) (P<0.05). The positive expression rate of VEGF protein in SHCC was 85% (34/40), which was significantly higher than that in the normal liver tissue from liver angioma (40%, 2/5) and SHCC adjacent liver tissue (42.8%, 15/35) (P<0.05). There was no expression correlation between CD82 and VEGF. The recurrence rate in CD82 negative SHCC group was 54.2%, which was significantly higher than that in CD82 positive SHCC group (18.8%) (P=0.026). The 1,2,3-year cumulative disease-free survival rates in CD82 positive SHCC group were 94%, 87%, 68%, those were higher than those in CD82 negative SHCC group (85%, 78%, 43% respectively). The recurrence rate in VEGF positive SHCC group was 47.1%, which was significantly higher than that in VEGF negative SHCC group(0) (P=0.035). The sensitivity and specificity of combined testing of CD82 and VEGF for diagnosing the recurrence of SHCC were 81.3% and 62.5% respectively. Conclusion] The expressions of CD82 and VEGF were correlated to recurrence of SHCC. CD82 might become a predictive marker for the recurrence of SHCC.